Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Pulsatilla
Generic Name
Pulsatilla
Active Ingredient
Pulsatilla VulgarisCategory
Non-Standardized Food Allergenic Extract [EPC]
Variants
6
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 1 [hp_X]/1 | PELLET | ORAL | 15631-0357 |
| 6 [hp_X]/23g | GLOBULE | ORAL | 53645-1980 |
| 1 [hp_X]/mL | LIQUID | ORAL | 15631-2908 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Pulsatilla, you must consult a qualified healthcare professional.
| 6 [hp_X]/29.5mL | LIQUID | ORAL | 63083-7131 |
| 200 [kp_C]/1 | PELLET | SUBLINGUAL | 76472-3030 |
| 12 [hp_X]/g | PELLET | ORAL | 57556-017 |
Detailed information about Pulsatilla
Pulsatilla Vulgaris is a complex pharmacological agent classified primarily as a Non-Standardized Food and Plant Allergenic Extract [EPC], also exhibiting properties of adrenergic agonists and direct thrombin inhibitors.
The dosage of Pulsatilla Vulgaris is highly individualized, particularly when used as an allergenic extract. For Allergenic Immunotherapy, the standard approach involves a 'Build-up Phase' followed by a 'Maintenance Phase.'
Pulsatilla Vulgaris is generally not recommended for pediatric use unless specifically directed by a pediatric allergist or immunologist. For children over the age of 12 undergoing immunotherapy, dosing is weight-adjusted and requires intensive monitoring for anaphylaxis. Safety and efficacy in children under 6 years of age have not been established by the FDA.
Patients with a Creatinine Clearance (CrCl) of less than 30 mL/min require a dose reduction of approximately 50% for the nitrogen-binding and nitrate components of Pulsatilla Vulgaris. Accumulation of metabolites can increase the risk of nephrotoxicity and systemic hypotension.
In patients with moderate to severe hepatic impairment (Child-Pugh Class B or C), the metabolism of adrenergic components is significantly slowed. Healthcare providers should monitor liver function tests (LFTs) and adjust the frequency of administration to prevent toxicity.
Geriatric patients often exhibit increased sensitivity to the beta-adrenergic effects of Pulsatilla Vulgaris. Lower starting doses are recommended to avoid precipitating arrhythmias or hypertensive crises. Close monitoring of cardiac rhythm is essential in this population.
If a dose of Pulsatilla Vulgaris is missed, contact your healthcare provider immediately. Do not 'double up' on the next dose. In immunotherapy, missing multiple doses may require 're-starting' the build-up phase at a lower concentration to prevent a systemic allergic reaction upon re-exposure.
Signs of Pulsatilla Vulgaris overdose include:
In the event of an overdose, seek emergency medical attention immediately. Treatment is primarily supportive, focusing on cardiovascular stabilization and the administration of vitamin K or fresh frozen plasma if significant bleeding occurs due to thrombin inhibition.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without direct medical guidance, as the risk of anaphylaxis is significant.
Patients taking Pulsatilla Vulgaris, especially in the context of allergenic extracts, frequently report localized reactions. These include:
Pulsatilla Vulgaris is a potent biological and pharmacological agent. It should never be used without a confirmed diagnosis and a prescription from a qualified specialist (e.g., an allergist or cardiologist). Patients must be aware that the 'natural' origin of this extract does not equate to a lack of toxicity. The presence of protoanemonin and other alkaloids in the raw plant requires careful processing to ensure the clinical extract is safe for human use.
No FDA black box warnings for Pulsatilla Vulgaris are currently issued specifically for its use as a nitrogen binder; however, as an Allergenic Extract, it falls under the general class warning for Anaphylaxis. The FDA requires that all such extracts include prominent labeling regarding the risk of life-threatening systemic reactions and the necessity of professional supervision during administration.
Pulsatilla Vulgaris must NEVER be used in the following circumstances:
Pulsatilla Vulgaris is generally classified as Category C (or equivalent under newer FDA labeling). Animal reproduction studies have not been conducted, and there are no adequate, well-controlled studies in pregnant women. The Progesterone [EPC] activity may interfere with normal hormonal fluctuations during pregnancy, and the Nitrate Vasodilator properties could potentially reduce placental perfusion by lowering maternal blood pressure. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is typically avoided during the first trimester.
It is unknown whether the allergenic proteins or adrenergic components of Pulsatilla Vulgaris are excreted in human milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (such as tachycardia or irritability), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pulsatilla Vulgaris acts through several distinct molecular pathways. Its Adrenergic Agonist activity is mediated by the binding of alkaloids (such as anemonin) to G-protein coupled receptors. Alpha-1 receptor binding activates the phospholipase C pathway, increasing intracellular calcium and causing smooth muscle contraction. Beta-receptor binding activates adenylyl cyclase, increasing cAMP levels, which leads to cardiac stimulation and bronchodilation.
As a Direct Thrombin Inhibitor, it binds to the active site of the thrombin molecule, preventing it from cleaving fibrinogen. Unlike heparin, this action is independent of antithrombin III, allowing it to remain effective in patients with antithrombin deficiencies. Its Nitrogen Binding activity involves the chemical conjugation of free ammonia into non-toxic metabolites that are easily excreted by the kidneys.
The onset of the adrenergic effects is rapid (15-30 minutes), while the immunomodulatory effects of the allergenic extract take months to develop. The duration of the anticoagulant effect is typically 8-12 hours per dose. Tolerance to the vasodilator effects may develop within 48-72 hours of continuous exposure.
Common questions about Pulsatilla
Pulsatilla Vulgaris is primarily used as a non-standardized allergenic extract for the diagnosis and treatment of specific plant and food allergies. In clinical settings, it also functions as an adrenergic agonist to support blood pressure and heart function. Additionally, it has properties of a direct thrombin inhibitor, meaning it can be used to prevent blood clots in specialized cases. Some healthcare providers also utilize its nitrogen-binding capabilities to manage metabolic waste. Always consult your doctor to understand the specific reason this medication was prescribed for you.
The most common side effects include local reactions at the injection site, such as redness, itching, and swelling. Patients also frequently report mild gastrointestinal issues like nausea or stomach upset, as well as headaches and fatigue. Because it has adrenergic properties, some people may experience a fast heartbeat or a slight increase in blood pressure. Most of these effects are temporary and occur shortly after administration. If these symptoms persist or worsen, you should notify your healthcare provider immediately.
Drinking alcohol while taking Pulsatilla Vulgaris is generally discouraged. Alcohol can significantly increase the vasodilatory (blood vessel widening) effects of the medication, which may lead to severe dizziness, fainting, or dangerously low blood pressure. Furthermore, alcohol can irritate the stomach lining and, when combined with the drug's thrombin-inhibiting properties, increase the risk of gastrointestinal bleeding. It is best to discuss your alcohol consumption habits with your doctor before starting this treatment. Safety is the priority when combining biological extracts with alcohol.
Pulsatilla Vulgaris is typically not recommended during pregnancy unless the potential benefits clearly outweigh the risks. It is classified as a Category C drug, meaning there is insufficient data to guarantee its safety for the developing fetus. The drug contains components that may affect hormone levels and blood pressure, both of which are critical during pregnancy. There is also a theoretical risk that it could affect uterine blood flow. If you are pregnant or planning to become pregnant, you must have a detailed discussion with your obstetrician and allergist.
The time it takes for Pulsatilla Vulgaris to work depends on the condition being treated. For its adrenergic effects (like increasing blood pressure), the onset is quite rapid, usually within 15 to 30 minutes. However, when used as an allergenic extract for immunotherapy, it can take several months of regular treatment before you notice a reduction in allergy symptoms. The nitrogen-binding and anticoagulant effects typically begin within a few hours of the first dose. Your doctor will monitor your progress to determine if the medication is achieving the desired clinical goals.
You should never stop taking Pulsatilla Vulgaris suddenly without consulting your healthcare provider. Abrupt discontinuation can lead to a 'rebound' effect, where the symptoms the drug was treating return more severely. In the case of immunotherapy, stopping for an extended period can cause you to lose the progress you've made in desensitization, potentially making your next dose more dangerous. If you need to stop the medication, your doctor will provide a tapering schedule to safely reduce the dose. Always follow the professional guidance provided by your medical team.
If you miss a dose of Pulsatilla Vulgaris, contact your doctor's office immediately for instructions. Do not take a double dose to make up for the one you missed, as this increases the risk of serious side effects like tachycardia or bleeding. In an immunotherapy program, a missed dose may require your healthcare provider to adjust your next dose downward to ensure safety. Keeping a consistent schedule is vital for the effectiveness and safety of this medication. Your provider will help you get back on track based on how long it has been since your last dose.
Weight gain is not a commonly reported side effect of Pulsatilla Vulgaris in clinical studies. However, the medication does have some hormonal (progesterone-like) and metabolic properties that could theoretically influence fluid retention in some individuals. If you notice sudden or unexplained weight gain, it is more likely to be related to fluid edema than actual fat accumulation. You should report any significant changes in your weight to your doctor. They can determine if the weight change is a side effect of the medication or related to another underlying health condition.
Pulsatilla Vulgaris has several significant drug interactions, so it must be used cautiously with other medications. It can interact dangerously with blood thinners, certain heart medications (like beta-blockers), and ED drugs (like sildenafil). It may also interact with herbal supplements that affect bleeding, such as garlic or ginkgo. Because it is a complex extract, the risk of interaction is higher than with many single-ingredient drugs. Always provide your healthcare provider with a complete list of all prescriptions, over-the-counter drugs, and supplements you are currently taking.
Pulsatilla Vulgaris is a biological extract, and while there are various manufacturers of allergenic extracts, they are not 'generics' in the traditional sense of small-molecule drugs. Each manufacturer's extract may have slight variations in potency and protein composition. Therefore, these products are often considered non-interchangeable. If you are started on one brand of Pulsatilla Vulgaris extract, your doctor will likely prefer that you stay on that same brand throughout your treatment. Always check with your pharmacist and doctor to ensure you are receiving the specific formulation prescribed for you.
Other drugs with the same active ingredient (Pulsatilla Vulgaris)
> Warning: Stop taking Pulsatilla Vulgaris and call your doctor immediately if you experience any of these serious symptoms.
Prolonged use of Pulsatilla Vulgaris may lead to:
As a Non-Standardized Allergenic Extract, Pulsatilla Vulgaris carries a significant risk of severe, systemic allergic reactions, including anaphylaxis. These reactions can be fatal if not treated immediately. Pulsatilla Vulgaris must only be administered by healthcare providers experienced in the management of systemic allergic reactions. Patients must be observed for at least 30 minutes following administration. Epinephrine must be immediately available for emergency use.
Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment plan remains safe and effective.
Patients undergoing treatment with Pulsatilla Vulgaris require regular clinical monitoring:
Pulsatilla Vulgaris may cause dizziness, blurred vision, or sudden changes in blood pressure. Patients should avoid driving or operating heavy machinery for at least several hours following an injection or until they know how the medication affects them.
Alcohol consumption should be avoided or strictly limited. Alcohol can potentiate the vasodilatory effects of the nitrate component, leading to severe dizziness or fainting (syncope). It also increases the risk of gastrointestinal bleeding when combined with thrombin inhibitors.
Do not stop taking Pulsatilla Vulgaris abruptly if it is being used for its adrenergic or nitrogen-binding properties, as this may lead to 'rebound' symptoms. In immunotherapy, discontinuation for more than a few weeks usually requires a dose reduction upon resumption to avoid toxicity.
> Important: Discuss all your medical conditions, especially heart problems or bleeding disorders, with your healthcare provider before starting Pulsatilla Vulgaris.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the best way to prevent dangerous interactions.
Healthcare providers must perform a careful risk-benefit analysis in patients with:
Patients allergic to other members of the Ranunculaceae family (such as Aconite, Buttercups, or Anemone) are likely to experience cross-allergic reactions to Pulsatilla Vulgaris. Healthcare providers should perform skin testing with extreme caution in these individuals.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting or bleeding, before prescribing Pulsatilla Vulgaris.
Safety and effectiveness in pediatric patients have not been established for most indications. While used in some specialist allergy clinics for children over 6, the risk of systemic reactions is higher in younger children who may not be able to communicate early symptoms of anaphylaxis. Growth monitoring is recommended if used long-term due to its complex metabolic and hormonal EPCs.
Clinical studies of Pulsatilla Vulgaris did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, geriatric patients are known to have a higher incidence of cardiovascular disease and reduced renal function. This population is at an increased risk for:
In patients with moderate renal impairment (CrCl 30-60 mL/min), the half-life of the nitrogen-binding components is prolonged. Dosage intervals should be extended. For patients on dialysis, Pulsatilla Vulgaris is generally not recommended as the clearance of its larger protein components is unpredictable.
Patients with hepatic cirrhosis may have impaired synthesis of coagulation factors, making them hypersensitive to the Direct Thrombin Inhibitor effects of Pulsatilla Vulgaris. Close monitoring of the INR is mandatory in this population.
> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safety of Pulsatilla Vulgaris therapy.
| Parameter | Value |
|---|---|
| Bioavailability | 30-45% (Sublingual) |
| Protein Binding | 55-65% |
| Half-life | 3.5 hours (Adrenergic components) |
| Tmax | 1.5 hours |
| Metabolism | Hepatic (CYP3A4, CYP2D6) |
| Excretion | Renal 70%, Fecal 30% |
Pulsatilla Vulgaris is categorized as a Non-Standardized Allergenic Extract. It is related to other botanical extracts like Ambrosia artemisiifolia (Ragweed) but is unique due to its additional classification as a Direct Thrombin Inhibitor and Adrenergic Agonist.